| Item type |
紀要論文 / Departmental Bulletin Paper(1) |
| 公開日 |
2018-12-06 |
| タイトル |
|
|
タイトル |
新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討 |
|
言語 |
ja |
| タイトル |
|
|
タイトル |
Combinatorial Treatment Using Leczyme as a New Candidate of Anti-Cancer Drug for Malignant Mesothelioma Cell Lines |
|
言語 |
en |
| 言語 |
|
|
言語 |
jpn |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Combination chemotherapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
drug resistance |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
malignant mesothelioma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sialic acid binding lectin |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 著者 |
佐藤, 稔之
立田, 岳生
菅原, 栄紀
原, 明義
細野, 雅祐
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Malignant mesothelioma is one of the aggressive cancer that results most commonly from exposure to asbestos. Treatment options of this cancer are limited even in the case of chemotherapy. Moreover, mesothelioma often becomes resistant to pemetrexed and cisplatin, the key drugs for the mesothelioma treatment. Sialic acid binding lectin isolated from rana catesbeiana oocytes（cSBL）shows remarkable anti-tumor effects caused by its ribonuclease activity in mesothelioma cells and exhibits high synergistic effect with pemetrexed. To find more effective combination regimen of cSBL, we examined currently estimated anti-mesothelioma drugs, TNF-related apoptosis-inducing ligand（TRAIL）and EGF receptor-tyrosine kinase inhibitors（erlotinib, gefitinib, and vandetanib）, by using pemetrexed-resistant cell lines, H28-PR and H2452-PR, in vitro. Consequently, the former showed slightly cross-resistance to gefitinib and the latter to cisplatin, cSBL, gefitinib, and vandetanib, respectively. In multiple drugs combination study, pemetrexed＋cSBL and pemetrexed＋cisplatin＋cSBL were higher effective than the other regimens from the aspects of antiproliferative and synergistic effects. Cleavage of Bid and caspase-3 protein which is the sign of apoptosis, and both downregulation of p21 and stabilization of cyclin A which is of cytostatic effects, were detected dependent on the drugs used in the combination treatments. According to these results, we estimated that pemetrexed＋cSBL＋TRAIL combination showed strong synergy by playing the role without any interference and may serve as a rational regimen with the object of anti-proliferative mechanism. In conclusion, our results indicated that cSBL-containing combination treatments show promise for the treatment of malignant mesothelioma. |
|
言語 |
en |
| 書誌情報 |
ja : 東北医科薬科大学研究誌
en : Journal of Tohoku Medical and Pharmaceutical University
号 64,
p. 65-76,
発行日 2017-12
|
| 出版者 |
|
|
出版者 |
東北医科薬科大学 |
|
言語 |
ja |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
2432-5724 |
| 権利 |
|
|
言語 |
en |
|
権利情報Resource |
https://creativecommons.org/licenses/by-nc-nd/3.0/deed.en |
|
権利情報 |
Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討 (2.7 MB)
.png)
